New photodisinfection study published
17/01/2023
ONDINE BIOMEDICAL INC.
("Ondine Biomedical", "Ondine" or the "Company")
New photodisinfection study published
Photodisinfection was found to eradicate biofilms associated with periprosthetic joint infections
· Periprosthetic joint infections are life-threatening and extremely hard-to-treat.
· The annual cost of treating periprosthetic joint infections in the US is $1.62 billion, with costs projected to rise to $1.85 billion by 2030 for hip and knee replacements alone.[1]
A new study published in the journal Antibiotics found that antimicrobial photodisinfection therapy (aPDT), using Ondine Biomedical Inc.'s (AIM: OBI) proprietary methylene blue-based photosensitizer in combination with a specific wavelength of light, effectively eradicated pathogen biofilms commonly associated with periprosthetic joint infections ("PJIs").
The results of this study suggest that photodisinfection could be used as an effective treatment method for PJIs, replacing current, more invasive approaches and potentially shortening antibiotic treatment. This would not only improve patients' quality of life, but also reduce morbidity, mortality, antibiotic resistance, and the high healthcare costs associated with treating these infections.
The in vitro study, conducted by a research team from University Hospital Zurich, found that photodisinfection achieved 100% kill of the key pathogens in biofilms associated with PJIs. These included the ESKAPE pathogens Staphylococcus aureus and Escherichia coli and also Staphylococcus epidermidis, and Cutibacterium acnes, with no regrowth.
The photodisinfection treatment did not cause any relevant surface modification on any of the different prosthesis materials, suggesting that the therapy does not harm the material and is safe to use in vivo.
Lead author and Senior Physician for Internal Medicine and Infectious Diseases at Zollikerberg Hospital, Dr. Yvonne Achermann, commented:
"This is the first study to show that photodisinfection, also known as photodynamic therapy (PDT), could be an effective novel treatment for periprosthetic joint infections. This is particularly exciting as it provides a much-needed alternative to antibiotics as resistance in biofilm-forming bacteria continues to grow. We [the research team at University Hospital Zurich] are planning a clinical safety study to further explore the potential of photodisinfection to treat and even prevent PJIs."
Patients undergoing major surgeries like hip or knee replacements face the risk of life-threatening infections with the majority of these related to the patients' own microflora, or bacteria naturally present on the body. PJIs are typically extremely hard to treat,[2] often requiring surgical intervention and prolonged treatment with high-dose antibiotics. In the US alone, the annual cost of treating PJIs is estimated at $1.62 billion.[3]
The full research paper can be accessed here. The University Hospital Zurich research team is planning further clinical studies of photodisinfection for the treatment of PJIs, starting with a clinical safety study.
|
Ondine Biomedical Inc. |
|
|
Angelika Vance, Corporate Communications |
+001 (1) 604 838 2702 |
|
|
|
|
Singer Capital Markets (Nominated Adviser and Joint Broker) |
|
|
Aubrey Powell, Asha Chotai, Sam Butcher |
+44 (0)20 7496 3000 |
|
|
|
|
RBC Capital Markets (Joint Broker) |
|
|
Rupert Walford, Kathryn Deegan |
+44 (0) 20 7653 4000 |
|
|
|
|
Vane Percy & Roberts (Media Contact) |
|
|
Simon Vane Percy, Amanda Bernard |
+44 (0) 77 1000 5910 |
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Ondine's nasal photodisinfection technology is approved in several jurisdictions under the brand name Steriwave™. It has been awarded the CE mark and, in the US, has been granted Qualified Infectious Disease Product designation and Fast Track status in the US by the FDA. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as nasal disinfection, sinusitis, ventilator-associated pneumonia, burns, and other indications.
About University Hospital Zurich
The University Hospital Zurich (USZ) is open to all patients every day and provides fundamental medical care and cutting-edge medicine in a central location in Zurich. We use our superior academic knowledge to treat a wide range of health issues, taking a personal touch and utilizing highly specialized and up-to-date research.
www.usz.ch/en/about-university-hospital-zurich/
[1] Premkumar A, Kolin DA, Farley KX, Wilson JM, McLawhorn AS, Cross MB, Sculco PK. Projected Economic Burden of Periprosthetic Joint Infection of the Hip and Knee in the United States. J Arthroplasty. 2021 May;36(5):1484-1489.e3. doi: 10.1016/j.arth.2020.12.005. Epub 2020 Dec 9. PMID: 33422392.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund